Picture EBD Group BIO-Europe 2020 Digital Event BEU2020 650x81
Document › Details

Abcodia Ltd.. (6/16/11). "Press Release: Abcodia Appoints Dr Wendy Alderton as Director of Science".

Organisations Organisation Abcodia Ltd.
  Organisation 2 GlaxoSmithKline (GSK) (Group)
Products Product biobank
  Product 2 biomarker
Person Person Barnes, Julie (Abcodia 201105 CEO before BioWisdom 200602 CSO)

Abcodia, a company engaged in the validation and discovery of molecular biomarkers for disease diagnosis and screening, is pleased to announce the appointment of Dr Wendy Alderton as its Director of Science to work with collaborative partners and take forward its vision to transform the way that life-threatening diseases are diagnosed.

Dr Alderton is an experienced biotechnology research leader with a background in molecular sciences. Her areas of expertise include oncology, neuroscience and inflammation, and project management gained at GlaxoSmithKline, Millennium Pharmaceuticals (UK), PIramed Ltd and Summit plc.

The appointment follows Abcodia's recent announcement that it had secured £1 million funding from venture capital investors Albion Ventures and UCL Business and would be investing in highly skilled staff to work with its growing number of collaborative partnerships.

Abcodia has been granted rights to commercialise IP from one of the largest biobanks in the UK created by lead clinical scientists at University College London, one of the world's leading research-led universities. Abcodia aims to make groundbreaking discoveries and improve the diagnosis of many common life-threatening and debilitating diseases, including the major cancers - colon, lung, pancreatic - as well as other conditions such as diabetes, osteoporosis and rheumatoid arthritis.

Dr Alderton said: "I am delighted to be joining Abcodia at such an exciting time in its development. There is already considerable interest in Abcodia's vision and capability and I am looking forward to supporting the company as it expands its international partnerships to advance the science of disease diagnosis and screening."

Abcodia's CEO, Dr Julie Barnes said: "Wendy's 18 years of expertise in molecular sciences and project management are perfect for us as we position our unique prospective serum biobank in the exciting and rapidly growing molecular diagnostics market. I am delighted to be able to welcome Wendy to the team."

*A digital image of Dr Alderton is available on request.


Abcodia is an innovative company engaged in the validation and discovery of molecular biomarkers. With its unique longitudinal serum biobank and partnerships with UCL, technology platform providers and leading commercial diagnostic companies, Abcodia is able to support the end-to-end diagnostic development process.

Please contact Press Officer, Ellee Seymour on 07939 811961 or by email

Record changed: 2015-08-22


Picture ConsulTech GmbH GDPR-compliant E-Col Cloud Document Management 650x80px

More documents for Abcodia Ltd.

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]


Picture EBD Group BIO-Europe 2020 Digital Event BEU2020 650x81

» top